Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Canakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia Trial

NCT04510493 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT04510493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04510493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Canakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia Trial
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Phase 3
Overall status
Completed
Start date
October 23, 2020
Completion date
August 17, 2021
Enrollment
116 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infection, diabetes mellitus, type 2